A Care Coordination Intervention Improves Symptoms But Not Charges in High-Risk Patients With Inflammatory Bowel Disease.


Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
05 2022
Historique:
received: 03 05 2021
revised: 17 08 2021
accepted: 23 08 2021
pubmed: 31 8 2021
medline: 20 4 2022
entrez: 30 8 2021
Statut: ppublish

Résumé

Inflammatory bowel disease (IBD) is associated with substantial symptom burden, variability in clinical outcomes, and high direct costs. We sought to determine if a care coordination-based strategy was effective at improving patient symptom burden and reducing healthcare costs for patients with IBD in the top quintile of predicted healthcare utilization and costs. We performed a randomized controlled trial to evaluate the efficacy of a patient-tailored multicomponent care coordination intervention composed of proactive symptom monitoring and care coordinator-triggered algorithms. Enrolled patients with IBD were randomized to usual care or to our care coordination intervention over a 9-month period (April 2019 to January 2020). Primary outcomes included change in patient symptom scores throughout the intervention and IBD-related charges at 12 months. Eligible IBD patients in the top quintile for predicted healthcare utilization and expenditures were identified. A total of 205 patients were enrolled and randomized to our intervention (n = 100) or to usual care (n = 105). Patients in the care coordinator arm demonstrated an improvement in symptoms scores compared with usual care (coefficient, -0.68, 95% confidence interval, -1.18 to -0.18; P = .008) without a significant difference in median annual IBD-related healthcare charges ($10,094 vs $9080; P = .322). In this first randomized controlled trial of a patient-tailored care coordination intervention, composed of proactive symptom monitoring and care coordinator-triggered algorithms, we observed an improvement in patient symptom scores but not in healthcare charges. Care coordination programs may represent an effective value-based approach to improve symptoms scores without added direct costs in a subgroup of high-risk patients with IBD. (ClinicalTrials.gov, Number: NCT04796571).

Sections du résumé

BACKGROUND
Inflammatory bowel disease (IBD) is associated with substantial symptom burden, variability in clinical outcomes, and high direct costs. We sought to determine if a care coordination-based strategy was effective at improving patient symptom burden and reducing healthcare costs for patients with IBD in the top quintile of predicted healthcare utilization and costs.
METHODS
We performed a randomized controlled trial to evaluate the efficacy of a patient-tailored multicomponent care coordination intervention composed of proactive symptom monitoring and care coordinator-triggered algorithms. Enrolled patients with IBD were randomized to usual care or to our care coordination intervention over a 9-month period (April 2019 to January 2020). Primary outcomes included change in patient symptom scores throughout the intervention and IBD-related charges at 12 months.
RESULTS
Eligible IBD patients in the top quintile for predicted healthcare utilization and expenditures were identified. A total of 205 patients were enrolled and randomized to our intervention (n = 100) or to usual care (n = 105). Patients in the care coordinator arm demonstrated an improvement in symptoms scores compared with usual care (coefficient, -0.68, 95% confidence interval, -1.18 to -0.18; P = .008) without a significant difference in median annual IBD-related healthcare charges ($10,094 vs $9080; P = .322).
CONCLUSIONS
In this first randomized controlled trial of a patient-tailored care coordination intervention, composed of proactive symptom monitoring and care coordinator-triggered algorithms, we observed an improvement in patient symptom scores but not in healthcare charges. Care coordination programs may represent an effective value-based approach to improve symptoms scores without added direct costs in a subgroup of high-risk patients with IBD. (ClinicalTrials.gov, Number: NCT04796571).

Identifiants

pubmed: 34461298
pii: S1542-3565(21)00914-9
doi: 10.1016/j.cgh.2021.08.034
pmc: PMC8882693
mid: NIHMS1737037
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT04796571']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1029-1038.e9

Subventions

Organisme : NIDDK NIH HHS
ID : T32 DK062708
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002241
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK109032
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI122098
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK125687
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM097117
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK118154
Pays : United States

Informations de copyright

Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Références

J Patient Rep Outcomes. 2017;2(1):24
pubmed: 29770803
Patient Prefer Adherence. 2019 Sep 13;13:1545-1556
pubmed: 31571837
J Patient Rep Outcomes. 2017;2(1):26
pubmed: 29888745
JAMA. 2018 Jun 5;319(21):2223-2224
pubmed: 29872845
Liver Int. 2020 Jul;40(7):1556-1563
pubmed: 32343467
JAMA. 2002 Oct 9;288(14):1775-9
pubmed: 12365965
Gut. 2020 Apr;69(4):658-664
pubmed: 31285357
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1847-1850.e1
pubmed: 30149146
Clin Gastroenterol Hepatol. 2017 Mar;15(3):385-392.e2
pubmed: 27645518
Am J Manag Care. 2016 Mar;22(3 Suppl):s51-60
pubmed: 27269903
Eur J Health Econ. 2011 Jun;12(3):273-83
pubmed: 20967482
Am J Gastroenterol. 2019 Mar;114(3):472-482
pubmed: 30410041
Clin Gastroenterol Hepatol. 2018 Nov;16(11):1777-1785
pubmed: 29654918
Br J Gen Pract. 2010 Jul;60(576):e305-18
pubmed: 20594432

Auteurs

Jeffrey A Berinstein (JA)

Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan. Electronic address: jberinst@med.umich.edu.

Shirley A Cohen-Mekelburg (SA)

Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.

Gillian M Greenberg (GM)

Department of Pediatrics, Children's Hospital of Michigan, Detroit, Michigan.

Daniel Wray (D)

Twine Clinical Consulting, Park City, Utah.

Sameer K Berry (SK)

Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan.

Sameer D Saini (SD)

Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.

A Mark Fendrick (AM)

Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; Center for Value-Based Insurance Design, University of Michigan, Ann Arbor, Michigan.

Megan A Adams (MA)

Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.

Akbar K Waljee (AK)

Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.

Peter D R Higgins (PDR)

Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, Michigan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH